| # | Title | Journal | Year | Citations |
|---|
| 1 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 | Cell Death and Differentiation | 2018 | 4,036 |
| 2 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2017 | 1,388 |
| 3 | American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control | Medicine and Science in Sports and Exercise | 2019 | 455 |
| 4 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial | Lancet Oncology, The | 2021 | 225 |
| 5 | Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025 | European Urology | 2017 | 209 |
| 6 | Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC) | Cancer | 2020 | 202 |
| 7 | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial | Cancer | 2020 | 201 |
| 8 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial | | 2020 | 160 |
| 9 | Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression | JAMA Oncology | 2016 | 154 |
| 10 | Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study | | 2018 | 151 |
| 11 | Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors | Advances in Therapy | 2019 | 145 |
| 12 | The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types | Cancer | 2020 | 116 |
| 13 | Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden | | 2018 | 111 |
| 14 | ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer | Clinical Cancer Research | 2019 | 104 |
| 15 | Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer | Journal of Clinical Oncology | 2020 | 102 |
| 16 | Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer | | 2017 | 99 |
| 17 | Role of Dopamine Receptors in the Anticancer Activity of ONC201 | Neoplasia | 2018 | 96 |
| 18 | Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer | European Urology | 2019 | 95 |
| 19 | Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors | Cancer | 2017 | 94 |
| 20 | Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib | Clinical Pharmacokinetics | 2019 | 92 |
| 21 | Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | Clinical Cancer Research | 2020 | 90 |
| 22 | Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling | European Urology | 2018 | 87 |
| 23 | Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report | Journal of the National Cancer Institute | 2022 | 74 |
| 24 | Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results | JAMA Oncology | 2017 | 73 |
| 25 | Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder‐preservation therapy for muscle‐invasive bladder cancer | Cancer | 2017 | 72 |
| 26 | Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas | Clinical Colorectal Cancer | 2016 | 67 |
| 27 | Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors | | 2020 | 62 |
| 28 | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer | Future Oncology | 2018 | 60 |
| 29 | Mutations in renal cell carcinoma | Urologic Oncology: Seminars and Original Investigations | 2020 | 58 |
| 30 | Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies | American Journal of Hematology | 2017 | 56 |
| 31 | Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study | Journal of Clinical Oncology | 2021 | 56 |
| 32 | Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma | European Journal of Endocrinology | 2022 | 55 |
| 33 | Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 | Cell Cycle | 2017 | 53 |
| 34 | Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions | Current Urology Reports | 2018 | 47 |
| 35 | Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial | Lancet Haematology,the | 2018 | 44 |
| 36 | Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis | European Urology | 2018 | 41 |
| 37 | Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas | Clinical Lymphoma, Myeloma and Leukemia | 2019 | 37 |
| 38 | The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma | Cell Death and Disease | 2018 | 35 |
| 39 | Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication | Clinical Cancer Research | 2020 | 35 |
| 40 | Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer | Oncologist | 2019 | 32 |
| 41 | Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial | Nature Medicine | 2023 | 31 |
| 42 | BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations | Oncotarget | 2017 | 29 |
| 43 | Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study | Gynecologic Oncology | 2019 | 28 |
| 44 | Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy | Oncologist | 2020 | 28 |
| 45 | Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients | Cancer Investigation | 2015 | 27 |
| 46 | Central nervous system prophylaxis in diffuse large B‐cell lymphoma | European Journal of Haematology | 2016 | 27 |
| 47 | Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib | JAMA Oncology | 2018 | 26 |
| 48 | Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants | Oncologist | 2020 | 26 |
| 49 | Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies | European Urology Oncology | 2019 | 25 |
| 50 | Programming of Donor T Cells Using Allogeneic Delta-like Ligand 4-Positive Dendritic Cells to Reduce Gvhd but Retain GVL Activity | Blood | 2015 | 25 |
